A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809
Launched by GLAXOSMITHKLINE · Feb 20, 2007
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion criteria:
- • Healthy adult male smoker between the ages of 18 and 50 years
- • Body weight greater than 50kg and BMI between 18.5-29.9 kg/m2.
- • No abnormalities on the medical, psychiatric or laboratory evaluation
- • Smoke on average more than 20 but less that 40 cigarettes per day for the past year and not tried to give up in the 3 months before the study.
- Exclusion criteria:
- • History of psychiatric disorder or sleep disorder.
- • Receiving treatment for smoking cessation.
- • Use tobacco products other than cigarettes.
Trial Officials
GSK Clinical Trials
Study Director
GlaxoSmithKline
About Glaxosmithkline
GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Berlin, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials